Tarsus Pharmaceuticals (NASDAQ:TARS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
While shareholders of Tarsus Pharmaceuticals (NASDAQ:TARS) are in the black over 3 years, those who bought a week ago aren't so fortunate [Yahoo! Finance]
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.